Hyperintense acute reperfusion marker associated with hemorrhagic transformation in the WAKE-UP trial.
Anke WoutersLauranne ScheldemanPatrick DupontBastian ChengMartin EbingerMärit JensenMatthias EndresChristian GerloffKeith W MuirNorbert NighoghossianSalvador PedrazaClaus Z SimonsenFlorent BoutitieVincent ThijsGötz ThomallaJochen FiebachRobin LemmensPublished in: European stroke journal (2021)
In the WAKE-UP trial, the incidence of HARM was only 6% at 24 h. An association was present between HARM and hemorrhagic complications, but no relationship with functional outcome was observed.
Keyphrases
- phase iii
- study protocol
- phase ii
- risk factors
- clinical trial
- liver failure
- acute myocardial infarction
- respiratory failure
- cerebral ischemia
- open label
- coronary artery disease
- left ventricular
- extracorporeal membrane oxygenation
- mechanical ventilation
- percutaneous coronary intervention
- acute respiratory distress syndrome